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Introduction: Abatacept is a fusion protein of human cytotoxic T-lymphocyte–associated protein (CTLA)-4 and
the Fc portion of human immunoglobulin G1 (IgG1). It is believed to be effective in the treatment of rheumatoid
arthritis by inhibiting costimulation of T cells via blocking CD28–B7 interactions as CTLA-4 binds to both B7.1
(CD80) and B7.2 (CD86). However, the interaction of CD28 with B7 molecules is crucial for activation of naive cells,
whereas it is unclear whether the action of already activated CD4+ T cells, which are readily present in established
disease, also depends on this interaction. The aim of this study was to determine whether the mode of action of
abatacept depends solely on its ability to halt T cell activation in established disease.
Methods: Arthritis was induced in thymectomized male DBA/1 mice by immunisation with bovine collagen type II.
The mice were subsequently depleted for CD4+ T cells. Abatacept or control treatment was started when 80 % of
the mice showed signs of arthritis. Arthritis severity was monitored by clinical scoring of the paws, and anti-collagen
antibody levels over time were determined by enzyme-linked immunosorbent assay.
Results: Treatment with abatacept in the absence of CD4+ T cells resulted in lower disease activity. This was associated
with decreasing levels of collagen-specific IgG1 and IgG2a antibodies, whereas the antibody levels in control or CD4+
T cell–depleted mice increased over time.
Conclusions: These results show that abatacept decreased disease activity in the absence of CD4+ T cells, indicating
that the mode of action of abatacept in established arthritis does not depend entirely on its effects on CD4+ T cell
activation.Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory auto-
immune disease affecting the joints in approximately 1 %
of the world’s population [1, 2]. Patients with RA can
be treated with non-steroidal anti-inflammatory drugs
(NSAIDs) or with disease-modifying anti-rheumatic drugs
(DMARDs). NSAIDs can alleviate disease symptoms, but
they do not impede the underlying inflammatory events
or inhibit joint destruction; however, DMARDs do affect
the disease process in all these respects [3]. Abatacept,
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article, unless otherwise stated.associated protein (CTLA)-4 and the Fc portion of human
immunoglobulin G1 (IgG1), is a (biologic) DMARD and is
an effective therapy for established RA [4, 5]. It is believed
to be effective by blocking the costimulation of T cells
through disruption of CD28–B7 interactions as CTLA-4
binds to B7.1 (CD80) and B7.2 (CD86) on antigen-
presenting cells (APCs) [6].
CTLA-4-Ig has been tested in the collagen-induced
arthritis (CIA) model in mice and rats as a preventative
treatment and on the first day of clinical onset, result-
ing in lower clinical scores and reduced joint damage
[7–9]. However, abatacept is used to treat RA patients
in whom anti–tumour necrosis factor (anti-TNF) treat-
ment has failed. It is likely that, in this phase of
disease, the underlying autoimmune response is fully
matured. Likewise, it is conceivable that the action ofle is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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T cell responses, as fully developed T cell responses are
less dependent on CD28 costimulation. Indeed, CD28–B7
interactions are important for the activation of naive T
cells, but this is less well established for the activation of
memory CD4+ T cells [10]. CD28-B7 costimulation of
memory CD4+ T cells has been described as disturbing
interleukin (IL)-2 production and proliferation; however,
production of other cytokines and expression of activation
markers CD25 and CD69 are not affected, indicating an
incomplete dependence on this pathway [11]. Therefore, it
is of interest to study the effect of abatacept in the estab-
lished phase of arthritis models, as it is more similar to
the human situation with respect to the developmental
phase of the underlying autoimmune response. In ad-
dition, much can be learned about the pathogenesis of
human disease by understanding the mode of action
of therapeutic interventions. The latter is exemplified
through the use of anti-TNF or IL-6R blocking agents, for
example, showing the pivotal role of these cytokines in
inflammation. Nonetheless, the exact mode of action of
several DMARDs used in RA treatment, such as metho-
trexate or sulfasalazine, is still largely unclear.
Recently, researchers compared anti-TNF treatment
(adalimumab) with abatacept in a head-to-head study
revealing similar efficacy in time based on clinical, func-
tional and radiographic outcomes [12]. Intriguingly,
anti-TNF therapy is thought to have a quick mode of
action, as it directly inhibits inflammation by blocking
TNF, whereas abatacept is thought to be effective after a
longer time period, as the effect of costimulation block-
ade does not become apparent directly. Consequently,
similar efficacy of adalimumab and abatacept indicates a
different mode of action of abatacept in addition to cost-
imulation blockade. Therefore, in the present study, we
investigated whether the mode of action of abatacept
depends solely on its ability to halt T cell activation. We
report a decrease in disease progression and activity
after abatacept treatment in the absence of CD4+ T cells,
indicating that the mode of action of abatacept in estab-
lished arthritis does not depend entirely on its effects on
CD4+ T cell activation.
Methods
Mice
Male DBA/1 mice were obtained from our own breeding
colony (originally obtained from Charles River Laboratories,
Wilmington, Massachusetts, USA). Thymectomized DBA/1
mice were purchased from Harlan Laboratories (Boxmeer,
the Netherlands). All mice were housed under specific
pathogen-free conditions in individually ventilated cages at
the animal facility of Leiden University Medical Centre,
Leiden, the Netherlands. All experiments were performed
in accordance with Dutch national legislation andapproved by the ethics committee of the Animal Exper-
iments Committee of Leiden University (approval num-
bers 11085 and 12217).
Induction of CIA and evaluation of arthritis
CIA was induced in 8–10-week-old male DBA/1 mice as
described elsewhere [13]. A clinical score was assigned
based on a scoring protocol in which each swollen or
red phalanx was given 0.5 point and 1 point per toe. A
red or swollen knuckle was given 1 point, and a red or
swollen footpad and a swollen ankle and/or wrist were
given 5 points. The maximum score for each paw was
15 points, resulting in a maximum possible score of 60
points per mouse. Disease progression was monitored
for a maximum of 90 days after induction of CIA.
Change in clinical score was calculated by subtracting
the clinical score at the start of treatment for every scor-
ing time point after start of treatment until the end of
follow-up to correct for the difference in clinical score at
the start of treatment, as the mice did not develop
arthritis at the same time.
Treatment
Treatment was started when 80 % of the mice showed
signs of arthritis. The mice were randomised to the dif-
ferent treatment groups according to their scores to en-
sure that the mean clinical score of all groups was
comparable at the start of treatment. On day 0 of treat-
ment, 100 μg of GK1.5 (rat anti-mouse CD4 monoclonal
antibody [mAb]) was administered intraperitoneally to
the mice that underwent CD4+ T cell depletion to ac-
quire CD4 depletion at the start of treatment. This was
continued weekly until the end of the experiment. For
the different treatment regimens, mice received intraper-
itoneal injections of 500 μl of phosphate-buffered saline
(PBS), 100 μg of GK1.5, 1 mg of abatacept (Bristol-
Myers Squibb, Princeton, NJ, USA), 100 μg of GK1.5 in
combination with 1 mg of abatacept, 1 mg of isotype for
abatacept (Roche, Basel, Switzerland) or 1 mg of isotype
in combination with 100 μg of GK1.5 on days 1, 3, 5, 8,
12 and 19.
Evaluation of CD4+ T cell counts
To confirm that CD4+ T cell depletion after GK1.5 treat-
ment was complete, blood was collected on days 0, 12,
22 and 35 and at the end of the experiment. The blood
was lysed and subsequently stained with CD3 PerCP-
Cy5.5 (clone 145-2C11), CD4 fluorescein isothiocyanate
(clone RM4-4), CD8 allophycocyanin (Ly-2, clone 53–6.7),
all from BD Pharmingen (San Diego, CA, USA); and anti-
mouse CD45 eFluor 450 (clone 30-F11; eBioscience, San
Diego, CA, USA). All samples were evaluated by using a
BD LSRFortessa cell analyser (BD Biosciences, San Jose,
CA, USA) and analysed using BD FACSDiva software (BD
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Measurement of serum antibodies by enzyme-linked
immunosorbent assay
Anti–collagen type II and total IgG antibody levels were
determined as described elsewhere [14]. In short, Nunc
MaxiSorp plates (Thermo Scientific, Waltham, MA,
USA) were coated with 2 μg/ml bovine collagen type II
(Chondrex, Redmond, WA, USA) or 3 μg/ml murine col-
lagen type II (Chondrex) for antigen-specific antibodies or
with 0.5 μg/ml goat anti-mouse IgG (SouthernBiotech,
Birmingham, AL, USA) for total antibodies. IgG, IgG1
and IgG2a were detected using goat anti-mouse IgG–
horseradish peroxidase (HRP), goat anti-mouse IgG1-HRP
and goat anti-mouse IgG2a-HRP, respectively (all from
SouthernBiotech). Enzyme activity was visualised using
2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid.
Serial dilutions from pooled sera of arthritic mice were
used as a standard to calculate arbitrary units.
Measurement of supernatant antibody titres
After sacrifice bone marrow and spleen cells were isolated
and then 200,000 cells per well were cultured in Iscove’s
modified Dulbecco’s medium (Lonza BioResearch, Basel,
Switserland) containing 10 % foetal calf serum (Gibco; Life
Technologies, Carlsbad, CA, USA), GlutaMAX, penicillin,
streptomycin (Invitrogen, Carlsbad, CA, USA) and 2-
mercaptoethanol. After 7 or 14 days of culture, the
supernatant was harvested and total IgG levels were
determined by enzyme-linked immunosorbent assay
(ELISA).
Statistical analysis
Statistical analysis was performed using GraphPad Prism
version 5 (GraphPad Software, La Jolla, CA, USA). The
abatacept and CD4 depletion combination-treated group
and the control group were compared using Student’s t
test or the Mann–Whitney U test as appropriate accord-
ing to data distribution. P values <0.05 were considered
to be significant.
Results
Abatacept decreased disease activity in mice depleted of
CD4+ T cells by GK1.5
CTLA-4-Ig treatment has been used in the CIA model as
a preventative intervention [7–9]. However, CTLA-4-Ig
has not been tested in established disease, where most of
the disease-associated T cells are thought to be already
activated or to have differentiated into memory T cells.
Hence, it is not known whether its mode of action is also
mediated through T cell inhibition in this disease phase.
To investigate this mode of action, CIA was induced and
treatment was started when 80 % of the mice showedsigns of arthritis. One day before the start of treatment,
CD4+ T cells were depleted by intraperitoneal administra-
tion of the CD4+ T cell–depleting mAb GK1.5, and GK1.5
treatment was continued weekly until the end of follow-
up. Intriguingly, mice treated with the combination of
CD4 depletion and abatacept showed a significant de-
crease in disease activity compared with the mice treated
with GK1.5 only or with PBS control (Fig. 1b,c). In con-
trast, CD4 depletion only did not significantly alter arth-
ritis development compared with the control group
(Fig. 1b,c). Abatacept treatment in combination with CD4
depletion did not result in a lower number of affected
paws; however, combination treatment did reduce the
number of severely affected paws (clinical score ≥5)
(Fig. 1d,e). In addition, novel paws that developed inflam-
mation after the start of therapy displayed a lower disease
score. Thus, abatacept treatment did not prevent arthritis
development in unaffected joints, but it did reduce clinical
scores of affected joints (Fig. 1f,g). Similar results were
also obtained in an independent replication experiment
(data not shown).
To confirm complete CD4+ T cell depletion, CD4+
T cell frequencies were evaluated in the blood of GK1.5-
treated mice. On day 12 after the start of treatment,
CD4+ T cells were correctly depleted as expected. How-
ever, on day 53, CD4+ T cell depletion was not complete
anymore. In contrast, mice receiving the combination of
abatacept and CD4 depletion were still depleted of CD4+
T cells (Fig. 2a). This was also the case in the spleen and
inguinal lymph node (Fig. 2b). Examining the frequency
of CD4+ T cells over time indicated that, from day 12
onwards, the CD4+ T cell frequencies gradually in-
creased until the end of the experiment. Nonetheless,
over time, CD4+ T cell frequencies were still significantly
lower than in the groups that did not receive GK1.5
(Fig. 2c). In contrast, CD4+ T cells in the mice receiving
the combination of GK1.5 and abatacept treatment
remained depleted (Fig. 2c), conceivably as a result of
the prevention of the development of an anti-rat anti-
body response against GK1.5 by abatacept. Together,
these results show that abatacept is also effective in situ-
ations where CD4+ T cell numbers are greatly reduced,
suggesting a T cell–independent effect of abatacept that
inhibits the progression of arthritis.
Abatacept decreased disease activity in thymectomized
mice depleted of CD4+ T cells
Although the data presented above point to a CD4+
T cell–independent effect of abatacept in the treatment
of arthritis, they do not show such effects in a conclusive
manner for CD4+ T cells returned after initial depletion.
To ascertain that the CD4+ T cells were completely
depleted during the treatment, a more stringent method





Fig. 1 Abatacept decreased disease activity in mice depleted of CD4+ T cells by GK1.5. a Collagen-induced arthritis was induced in male DBA/1
mice. When 80 % of the mice showed signs of arthritis, treatment was started. One day before the start of treatment, CD4+ T cells were depleted by
intraperitoneal administration of GK1.5, and the depletion was continued until the end of follow-up. Treatment was administered by intraperitoneal
injection of either PBS (diamonds), GK1.5 (CD4 depletion) (squares), abatacept (circles) or a combination of GK1.5 and abatacept (triangles). The mice
were scored three times per week for inflammation in the paws to monitor disease progression. b Clinical scores over time of the different treatment
groups. c Changes in clinical scores starting from the day treatment was initiated in the different treatment groups. d Number of affected paws per
treatment starting from the day treatment was initiated. e Number of affected paws with a clinical score of 5 or higher (considered to be severely
affected paws) per treatment starting from the day treatment was initiated. f Clinical scores of paws that showed signs of arthritis at the start
of treatment and extending over time, per treatment. g Clinical scores of paws that did not show signs of arthritis at the start of treatment,
per treatment, over time. Values are mean ± SEM (n=11 per treatment group). Statistical analysis was performed using Student’s t test. *P < 0.05
abatacept + CD4 depletion vs CD4 depletion. CFA complete Freund’s adjuvant, IFA incomplete Freund’s adjuvant, PBS phosphate-buffered saline
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Fig. 2 Incomplete CD4+ T cell depletion by GK1.5 over time. The presence of CD4+ T cells in the blood was monitored over time using flow
cytometry. Blood was collected by making tail incisions during the experiment or by cardiac puncture at the of sacrifice. After red blood cell lysis,
blood mononuclear cells were cell-surface stained for CD45, CD3, CD4 and CD8. Cells were gated on CD45 and subsequently on CD3 and CD4.
a Dot plots of representative mice of each treatment group on day 12 and day 53 (end of experiment) after the start of treatment. b Summary of
the percentages of CD4+ T cells per treatment at the end of follow-up is depicted for the blood, spleen and inguinal lymph node (LN). Each
symbol represents 1 mouse. c Summary of CD4+ T cells in the blood over time as a percentage of the phosphate-buffered saline (PBS)-treated
group. Values are mean ± SEM (n=11 per treatment group). Statistical analysis was performed using Student’s t test. *P < 0.05 abatacept + CD4
depletion vs CD4 depletion. ns not significant
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after birth. After immunisation with collagen type II and
development of arthritis, CD4+ T cell depletion was per-
formed using GK1.5. Because the mice were thymecto-
mized, no new T cells could reappear in CD4+ T cell–
depleted mice. Again, we observed that treatment with
abatacept resulted in reduced disease activity in CD4+
T cell–depleted mice (Fig. 3b). Likewise, a reduced clin-
ical score for paws that were not arthritic at the start of
treatment was observed (Fig. 3c). We also noted a re-
duced number of severely affected paws, but abatacept
treatment did not prevent arthritis development in joints
not affected at the start of therapy (data not shown).
Abatacept-only treatment did not modulate the clinical
score compared with PBS treatment (data not shown).
To confirm that CD4+ T cells were completely depleted,
CD4+ T cell frequencies were monitored over time by
flow cytometry. Contrary to treatment with GK1.5 only
(Fig. 2), thymectomy in combination with GK1.5 treat-
ment resulted in complete depletion of CD4+ T cells in
mice that received CD4 depletion treatment (alone or in
combination with abatacept) (Fig. 3d). These results in-
dicate that abatacept treatment results in decreased dis-
ease activity in the absence of CD4+ T cells.
Reduced antibody levels after treatment with abatacept
in the absence of CD4+ T cells
Collagen type II–specific antibodies play a crucial role in
the development of CIA [15]. Therefore, collagen type
II–specific and total IgG levels were determined by ELISA
over time in sera of the thymectomized mice. Treatment
with abatacept in the absence of CD4+ T cells resulted in
decreased total IgG2a levels over time compared with
control treatment (Fig. 4). More importantly, decreases in
bovine collagen type II (immunisation antigen) and mur-
ine collagen type II (autoantigen) levels were also detected
after treatment with abatacept and GK1.5 (Fig. 4). This re-
sult was not specific for the IgG2a isotype, as decreased
IgG1 levels were observed as well (Fig. 4). Together, these
results indicate that abatacept treatment leads to reduc-
tions in disease activity and collagen-specific antibody
levels in the absence of CD4+ T cells.
Reduced antibody levels in supernatant of ex vivo
cultured spleen and bone marrow cells after treatment
with abatacept in the absence of CD4+ T cells
The data presented above suggest that abatacept treat-
ment could directly affect the number and/or activity of
antibody-secreting B cells. To study whether abatacept
in addition to the inhibition of costimulation of T cells
also affected the antibody-producing capacity of spleen-
and bone marrow–derived B cells, we next isolated
spleen and bone marrow cells from treated animals.
Total IgG levels in the supernatants of spleen and bonemarrow cells cultured ex vivo, but not stimulated, were
subsequently analysed by ELISA. Spleen cells of mice
treated with abatacept and CD4 depletion produced
lower IgG levels after 7 and 14 days of culture than did
spleen cells of mice that received only CD4 depletion
(Fig 5a), although the percentages of B cells and plasma
cells, as analysed by flow cytometry, were comparable
between the different treatment groups (data not
shown). This reduction in IgG production was also ob-
served in the supernatants of cultured bone marrow cells
(Fig 5b), indicating a loss of antibody-producing capacity
after abatacept treatment in the absence of CD4+ T cells.
Discussion
Abatacept is an effective treatment in RA and is thought
to block costimulation of T cells by inhibiting CD28–B7
interactions as abatacept binds to both B7.1 and B7.2
[6]. The interaction of CD28 with both B7 molecules is
crucially important for the activation of naive T cells,
whereas its role in the activation of already activated
and/or memory CD4+ T cells is less clear. As such CD4+
T cells are readily present in established disease, we
investigated whether abatacept is still effective in the ab-
sence of CD4+ T cells in the established disease phase of
the CIA model. Our study revealed that abatacept treat-
ment is able to decrease disease activity in the absence
of CD4+ T cells, indicating that the mode of action me-
diated by abatacept in CIA does not depend solely on its
ability to block costimulation of T cells. In addition, aba-
tacept treatment is capable of reducing collagen-specific
and total antibody levels in a T cell–independent setting.
To evaluate the mode of action of abatacept in estab-
lished disease, CD4+ T cells were depleted using the rat
anti-mouse CD4 antibody GK1.5. Remarkably, after 12
days of depletion, the CD4+ T cells gradually reappeared
in mice treated with GK1.5 only. Interestingly, the CD4+
T cells remained properly depleted in mice treated with
a combination of abatacept and GK1.5. This observation
is most likely explained by the notion that mice treated
with GK1.5 develop an anti-rat antibody response that
ultimately neutralises the CD4-depleting antibodies. This
phenomenon illustrates that abatacept is also capable of
blocking costimulation and thereby the activation of
naive T cells, preventing the development of the anti-rat
antibody response. Therefore, the depletion of CD4+ T
cells by GK1.5 in mice treated with abatacept resulted in
the complete and sustained depletion of CD4+ T cells
until the end of follow-up. For this reason, we also de-
pleted CD4+ T cells in thymectomized mice to prevent
the reappearance of new T cells when the GK1.5 treat-
ment became less effective, and we obtained similar
results.
Our results indicate that CD4+ T cells are not required




Fig. 3 Abatacept decreased disease activity in thymectomized mice depleted of CD4+ T cells. a Collagen-induced arthritis was induced in male
DBA/1 mice 2 weeks after they were thymectomized. When 80 % of the mice showed signs of arthritis, treatment was started. One day before
the start of treatment, CD4+ T cells were depleted by intraperitoneal administration of GK1.5 and then the depletion was continued until the end of
follow-up. Treatment was administered by intraperitoneal injection of PBS (diamonds), GK1.5 (squares; CD4 depl) or the combination of GK1.5 and
abatacept (triangles; Aba + CD4 depl). The mice were scored three times per week for inflammation in the paws to monitor disease progression.
b Clinical scores and changes in clinical scores starting from the day treatment was initiated in the different treatment groups (experiment 1; n=10 per
treatment group). The same experiment was independently repeated in another 10 mice per treatment group, and an isotype for abatacept was used
as control treatment (diamonds; iso) and in combination with CD4 depletion (cross symbols; iso + CD4 depl) (experiment 2). Changes in clinical scores
starting from the day treatment was initiated are depicted. c The clinical scores of the paws that did not show signs of arthritis at the start of treatment are
depicted for experiments 1 and 2. d The frequency of CD4+ T cells in blood at the end of follow-up was determined by flow cytometry. Abatacept-only
treatment is not depicted to improve the readability of the graphs. Values are mean ± SEM. Statistical analysis was performed using Student’s t test.
*P < 0.05 abatacept + CD4 depletion vs control group. CFA complete Freund’s adjuvant, IFA incomplete Freund’s adjuvant, ns not significant,
PBS phosphate-buffered saline
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parable disease progression or a trend towards more se-
vere disease progression compared with the control
groups. These observations are in line with the observa-
tion by Morgan et al., who reported that lethal irradi-
ation of mice with CIA, followed by syngeneic bonemarrow transplantation, resulted in continuation of the
disease even though the T cells were depleted [16]. Thus,
CD4+ T cells are not required for arthritis progression
once the disease clinically manifests in the CIA model.
Our presented results were obtained in a mouse model;
however, it is not known whether abatacept has a direct
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Fig. 4 Reduced antibody levels after treatment with abatacept in the absence of CD4+ T cells. Antibody levels were determined by enzyme-linked
immunosorbent assay over time. Serum samples were collected on days 0, 12, 21, 22, 35 and 47/48 after the start of treatment, and total IgG2a and
IgG1 levels were determined in the thymectomized mice. In addition, bovine and mouse collagen type II–specific IgG2a and IgG1 levels were determined.
a Levels are depicted as percentages of day 0. b An independent experiment including the isotype for abatacept. Abatacept-only treatment is not
depicted to improve the readability of the graphs, but it showed results comparable to those for abatacept + CD4 depletion. Levels are depicted as
percentages of day 0. Values are mean ± SEM (n=10 per treatment group). Statistical analysis was performed using the Mann–Whitney U test. *P < 0.05
abatacept + CD4 depletion vs control group. AU arbitrary units, bCII bovine collagen type II, CII collagen type II, IgG immunoglobulin G, mCII mouse
collagen type II, PBS phosphate-buffered saline
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humans. Nonetheless, in a recent study of RA in which
researchers compared anti-TNF and abatacept treatment
head to head, comparable efficacy was observed based
on clinical, functional and radiographic outcomes [12].
Intriguingly, no difference in the rate of response was
noted, as similar improvements were observed over
time. As one could speculate that a T cell–targeting drug
would require more time than a TNF inhibitor to mani-
fest its beneficial effects, this observation could be
compatible with the notion that abatacept has a differentmode of action in addition to its blocking effect on
T cell costimulation in humans.
The observation that abatacept is capable of decreas-
ing disease activity in the absence of CD4+ T cells does
not contradict the dogma that the mode of action of
abatacept is mediated through blockade of costimulation
and thereby activation of (naive) CD4+ T cells. However,
our results do indicate that abatacept has another mode
of action in addition to its effects on costimulation. A
limitation of our study is that we did not elucidate the
mechanism responsible for the inhibitory effect of
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Fig. 5 Abatacept decreased antibody levels detected in supernatants of ex vivo spleen and bone marrow cells in the absence of CD4+ T cells.
After the animals were sacrificed, spleen and bone marrow cells were collected and cultured without stimulation for 7 or 14 days and then IgG
production was measured in the supernatants by enzyme-linked immunosorbent assay. a Summary of the IgG levels detected in supernatants of
spleen cells collected in experiments 1 and 2. The IgG levels of the phosphate-buffered saline (PBS)- and isotype-treated mice are combined and
depicted as ‘PBS’, and the CD4 depletion and combination of isotype- and CD4 depletion–treated groups are combined and depicted as ‘CD4
depletion’. b Summary of the IgG levels detected in supernatants of bone marrow cells cultured for 7 or 14 days in experiments 1 and 2. Statistical
analysis was performed using the Mann–Whitney U test. *P < 0.05 abatacept + CD4 depletion vs control group. AU arbitrary units, IgG immunoglobulin G
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different from other DMARDs, such as methotrexate,
for which the exact mode of action also has not been
elucidated. Nonetheless, it would be interesting to delin-
eate these additional modes of action [17], as it could
allow for a more refined targeted therapy and additional
insights into the aetiological pathways of disease.
Recently, Rozanski et al. described that CD28 serves as
a survival factor for long-lived plasma cells. Loss of
CD28 or B7.1 (CD80) and B7.2 (CD86) caused sig-
nificant loss of long-lived plasma cells, resulting in de-
creased antibody titres [18]. As abatacept prevents the
binding of CD28 to CD80 and/or CD86, this survival
signal could be abrogated and lead to loss of plasma cells
and consequently a decrease in antibody titres. Indeed,
this would be in line with our observation of decreased
antibody levels after abatacept treatment and reduction
of clinical scores, as well as our observation of decreased
antibody production by cultured spleen and bone mar-
row cells from CD4+ T cell–depleted mice treated with
abatacept. Likewise, in the BXD2 mouse model of auto-
immune disease, it has been reported that elevated expres-
sion of activation-induced cytidine deaminase (AID) in
recirculating follicular CD86+ B cells and increasedgerminal centre activity are associated with the production
of autoantibodies [19]. Treatment with CTLA-4-Ig re-
sulted in normalisation of AID expression in the B cells
and suppression of IgG autoantibodies, which could ex-
plain the decrease in IgG titres we observed after abata-
cept treatment in the absence of CD4+ T cells.
The CD4+ T cell–independent effect of abatacept could
also be explained by the induction of nitric oxide synthase
or indoleamine 2,3-dioxygenase (IDO) by APCs [20–22].
IDO is an enzyme that degrades the essential amino acid
tryptophan, resulting in local depletion of tryptophan [23],
which leads to cell cycle arrest [24, 25] and thereby to
inhibition of T cell proliferation and expansion of the
immune response [26–28]. IDO has been implicated in
disease aetiology, as, for example, it has been reported that
CTLA-4 on regulatory T cells can induce IDO in APCs
[29] but regulatory T cells from RA patients failed to in-
duce such expression owing to low CTLA-4 expression
[30]. In addition to the suppressive effect of IDO on pro-
liferating effector T cells, IDO-expressing dendritic cells
are able to promote the activation of regulatory T cells
[31] and the differentiation of naive T cells to regulatory
T cells [23, 32], which could explain the inflammation-
suppressing effects of abatacept. However, Davis et al. [33]
Jansen et al. Arthritis Research & Therapy  (2015) 17:220 Page 10 of 11reported inhibition of naive and memory T cell prolifera-
tion and effector function in the absence of IDO induc-
tion, indicating that abatacept could also have other
mechanisms of action.
Abatacept could also have an effect on osteoclast pre-
cursors, explaining the anti-erosive effects of abata-
cept [34, 35], or on monocytes by modulating their
migratory capacity [36]. Direct effects on macrophages
have also been described resulting in decreased cytokine
production and reduction of the inflammatory reaction
[37–40], which could account for the beneficial effects
in the treatment of RA.
Conclusions
Abatacept is thought to block costimulation of T cells by
blocking the interaction between CD28 and B7, resulting
in inhibition of T cell activation. However, abatacept re-
duced disease progression and activity in the absence of
CD4+ T cells in the CIA mouse model, indicating that aba-
tacept can exert its action in established arthritis inde-
pendently of its effects on CD4+ T cell activation. Because
a head-to-head comparison of anti-TNF and abatacept
treatment resulted in comparable efficacy with a similar
time course, it is tempting to speculate that abatacept
could have an effect on other cell types in addition to
T cells in human RA as well.
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